Mid-regional pro-adrenomedullin in the early evaluation of acute chest pain patients

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 1048-1055

  Haaf, Philip ^a   Twerenbold, Raphael ^a   Reichlin, Tobias ^a   Faoro, Jonathan ^a   Reiter, Miriam ^a   Meune, Christophe ^b   Steuer, Stephan ^c   Bassetti, Stefano ^d   Ziller, Ronny ^a   Balmelli, Cathrin ^a   Campodarve, Isabel ^e   Zellweger, Christa ^a   Kilchenmann, Ashley ^a   Irfan, Affan ^a   Papassotiriou, Jana ^f   Drexler, Beatrice ^a   Mueller, Christian ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Emergency Department   (Switzerland)

^d Department of Internal Medicine ^*  (Switzerland)

^e HOSPITAL DEL MAR   (Spain)

^f THERMO FISHER SCIENTIFIC   (Germany)

Author keywords

Acute myocardial infarction; Chest pain; GRACE score; Mid regional pro adrenomedullin; TIMI risk score

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; COPEPTIN; MID REGIONAL PROADRENOMEDULLIN; PROADRENOMEDULLIN; TROPONIN T; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GRACE SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THORAX PAIN; TIMI SCORE;

ACUTE MYOCARDIAL INFARCTION; CHEST PAIN; GRACE SCORE; MID-REGIONAL PRO-ADRENOMEDULLIN; TIMI-RISK SCORE;

ACUTE DISEASE; ADRENOMEDULLIN; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHEST PAIN; COHORT STUDIES; EARLY DIAGNOSIS; FEMALE; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN PRECURSORS;

EID: 84885290211     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.10.025     Document Type: Article

References (37)

1. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-42.
2. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for Treatment of Infarcting Myocardium Early II trial substudy. Circulation 2000;102:2031-7.
3. Tiemann O. Variations in hospitalisation costs for acute myocardial infarction -a comparison across Europe. Health Econ 2008;17:S33-45.
4. Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides 2001;22:1693-711.
5. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000;21:138-67.
6. Ehlenz K, Koch B, Preuss P, Simon B, Koop I, Lang RE. High levels of circulating adrenomedullin in severe illness: correlation with C-reactive protein and evidence against the adrenal medulla as site of origin. Exp Clin Endocrinol Diabetes 1997;105:156-62.
7. Kobayashi K, Kitamura K, Hirayama N, et al. Increased plasma adrenomedullin in acute myocardial infarction. Am Heart J 1996;131:676-80.
8. Miyao Y, Nishikimi T, Goto Y, et al. Increased plasma adrenomedullin levels in patients with acute myocardial infarction in proportion to the clinical severity. Heart 1998;79:39-44.
9. Meeran K, O'Shea D, Upton PD, et al. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab 1997;82:95-100.
10. Pio R, Martinez A, Unsworth EJ, et al. Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J Biol Chem 2001;276:12292-300.
11. Lewis LK, Smith MW, Yandle TG, Richards AM, Nicholls MG. Adrenomedullin(1-52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. Clin Chem 1998;44:571-7.
12. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005;51:1823-9.
13. Reiter M, Twerenbold R, Reichlin T, et al. Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. Eur Heart J 2011;32:1379-89.
14. Thygesen K, Alpert JS,White HD, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-53.
15. Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. Circulation 2007;115:e352-5.
16. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010;56:254-61.
17. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-9.
18. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
19. Vickers AJ, Cronin AM, Begg CB. One statistical test is sufficient for assessing new predictive markers. BMC Med Res Methodol 2011;11:13.
20. Pencina MJ, D'Agostino Sr RB, D'Agostino Jr RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72 [discussion 207-12].
21. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004;291:2727-33.
22. Romanens M, Ackermann F, Spence JD, et al. Improvement of cardiovascular risk prediction: time to review current knowledge, debates, and fundamentals on how to assess test characteristics. Eur J Cardiovasc Prev Rehabil 2010;17:18-23.
23. Khan SQ, O'Brien RJ, Struck J, et al. Prognostic value of midregional proadrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2007;49:1525-32.
24. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma adrenomedullin as an indicator of prognosis after acute myocardial infarction. Heart 1999;81:483-7.
25. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55:2062-76.
26. Potocki M, Breidthardt T, Reichlin T, et al. Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. Crit Care 2009;13:R122.
27. von Haehling S, Filippatos GS, Papassotiriou J, et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010;12:484-91.
28. Beltowski J, Jamroz A. Adrenomedullin-what do we know 10 years since its discovery? Pol J Pharmacol 2004;56:5-27.
29. Hofbauer KH, Jensen BL, Kurtz A, Sandner P. Tissue hypoxygenation activates the adrenomedullin system in vivo. Am J Physiol Regul Integr Comp Physiol 2000;278: R513-9.
30. de Lemos JA,MorrowDA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345: 1014-21.
31. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002;40:437-45.
32. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106:2913-8.
33. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
34. Haaf P, Reichlin T, Corson N, et al. B-type natriuretic peptide in the early diagnosis and risk stratification of acute chest pain. Am J Med 2011;124:444-52.
35. Walter T, Brueckmann M, Lang S, et al. Comparison of long-term prognostic value of N-terminal-proBNP and midregional-pro-adrenomedullin in patients with acute myocardial infarction. Clin Lab 2010;56:303-9.
36. Schnabel RB, Schulz A, Messow CM, et al. Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J 2010;31: 3024-31.
37. Lyon R, Morris AC, Caesar D, Gray S, Gray A. Chest pain presenting to the emergency department-to stratify risk with GRACE or TIMI? Resuscitation 2007;74:90-3.